FibroGen Earnings Call: Cash-Rich, Data-Heavy, Unproven

FibroGen ((KYNB)) has held its Q4 earnings call. Read on for the main highlights of the call.

FibroGen’s latest earnings call painted a cautiously optimistic picture, as management highlighted a transformed balance sheet, aggressive cost cuts, and encouraging early oncology data, set against steep revenue declines and a weak fourth quarter. Executives stressed that the company now has cash visibility into 2028, but admitted that key value drivers hinge on clinical readouts still several years away.

Balance Sheet Overhaul and Extended Cash Runway

FibroGen completed the sale of FibroGen China to AstraZeneca and used proceeds to pay off its senior secured term loan, meaning the company now carries no such debt. Management reported $109.4 million in cash, cash equivalents, investments, and receivables at year-end 2025, which they believe funds operations into 2028 and stabilizes the platform for clinical execution.

Aggressive Cost Cuts Reshape Operating Profile

The company delivered a dramatic reset of its cost base in 2025, with total operating costs and expenses dropping to $52.3 million from $180 million a year earlier, a roughly 71% reduction. R&D spending fell 75.4% to $23.5 million while SG&A declined 43.8% to $27.7 million, signaling a narrower, more focused pipeline strategy but also a leaner growth engine.

Narrowed Full-Year Loss, But Not Yet Profitable

FibroGen’s net loss from continuing operations improved meaningfully, shrinking to $58.2 million, or $14.40 per share, from $153.1 million, or $38.26 per share, in 2024. Management framed this roughly 62% improvement in absolute net loss and per-share losses as evidence that the restructuring is working, even though the business remains firmly in loss-making territory.

FG-3246/FG-3180: Early Efficacy in Prostate Cancer

In metastatic castration-resistant prostate cancer, the CD46-targeted antibody-drug conjugate FG-3246 and imaging agent FG-3180 delivered encouraging early data. An investigator-sponsored trial combining FG-3246 with enzalutamide showed median radiographic PFS of seven months overall and 10.1 months in patients who had progressed on one prior ARPI, with a 40% PSA50 response in that subgroup and solid signals even in heavily pretreated monotherapy patients.

Biomarker and Diagnostic Strategy for CD46 Program

Management highlighted FG-3180 PET uptake as a potential companion diagnostic, noting a trend toward higher PSA50 responses in patients with higher tumor SUV values, although this correlation narrowly missed conventional statistical significance. Still, the company sees a U.S. addressable market above $5 billion for FG-3246 and pointed to nearly $2 billion in 2025 PSMA PET agent sales as proof that targeted imaging platforms can scale commercially.

Phase 2 Trial Design and Upcoming Milestones

FibroGen has launched a phase 2 dose-optimization trial for FG-3246 monotherapy in post-ARPI, pre-chemotherapy mCRPC, enrolling 75 patients across three dose levels. The study will evaluate PSA50, objective response, safety, pharmacokinetics, and the FG-3180 SUV biomarker, with an interim update expected in 2026 and mature rPFS data anticipated in 2027, against a commercial benchmark of 10 months or more.

Safety Refinements and Neutropenia Management

Safety has been a key focus for the CD46 program after earlier neutropenia signals in phase 1. The investigator-sponsored trial showed that primary G-CSF prophylaxis substantially reduced grade 3 or higher neutropenia, and these learnings have been incorporated into the phase 2 design so that ADC exposure can be maintained while limiting dose interruptions and preserving efficacy.

Roxadustat: Orphan Status and New MDS Opportunity

Beyond oncology, roxadustat gained traction in anemia associated with lower-risk myelodysplastic syndromes, where it was granted Orphan Drug Designation in the U.S. A post-hoc analysis in high transfusion burden patients showed 36% achieving at least eight weeks of transfusion independence versus 7% on placebo, with a nominally significant p-value, and FibroGen has now submitted a phase 3 protocol to regulators.

Revenue Collapse Highlights Post-Transaction Reality

Despite financial de-risking, FibroGen’s topline suffered sharply, with Q4 2025 revenue falling to $1.3 million from $3.1 million a year earlier and full-year revenue dropping 78.4% to $6.4 million from $29.6 million. Management tied this to reduced commercial and licensing contributions after strategic transactions, underscoring that near-term fundamentals rely more on cost control than on revenue growth.

Weak Fourth Quarter Masks Full-Year Progress

The fourth quarter underscored ongoing earnings volatility, as net loss from continuing operations widened to $14.6 million, or $3.61 per share, versus $8.7 million, or $2.15 per share, in the prior-year period. Q4 total operating costs climbed 43.7% to $14.8 million, revealing execution and spending fluctuations even as full-year metrics showed improvement.

Biomarker Uncertainty and Data Limitations

While the biomarker strategy around FG-3180 remains a key differentiator, the company acknowledged that the observed link between PET uptake and response did not reach standard thresholds for statistical significance. This means the predictive value of CD46 imaging must still be proven in the larger phase 2 trial, adding scientific risk to the thesis that the PET agent can reliably guide therapy.

Execution Timelines and Readout Risk

FibroGen’s valuation now rests heavily on future milestones, with the FG-3246 phase 2 interim analysis not expected until 2026 and mature rPFS data slated for 2027, while roxadustat’s next pivotal step is a phase 3 trial planned for the second half of 2026. These long-dated timelines expose investors to clinical and regulatory risk, as any delay or disappointing result could materially affect the company’s trajectory.

Commercial and Partnering Strategy Still Unclear

On commercialization, management signaled openness to partnerships for both roxadustat and the PET imaging agent, noting that the company lacks deep PET diagnostic commercialization experience relative to incumbents. However, no binding business development agreements were announced, leaving significant uncertainty around how FibroGen will ultimately market or monetize these assets if data confirm their potential.

Competitive Pressures and Treatment Sequencing Challenges

The company also faces a complex competitive landscape, with established PSMA-targeted therapies and radioligand treatments already embedded in prostate cancer care. Key opinion leaders have suggested that both high- and low-SUV patients might benefit from CD46-targeted approaches, but this complicates clear patient selection and sequencing in a market crowded with differentiated, and often entrenched, alternatives.

Guidance and Outlook: Funded to 2028, Data-Driven Upside

Looking ahead, FibroGen reiterated that its $109.4 million cash position provides a runway into 2028, supporting ongoing clinical work in mCRPC and MDS. Management outlined key milestones, including the FG-3246 phase 2 interim data in 2026, mature rPFS in 2027, and a potential phase 3 start for roxadustat in the second half of 2026, while emphasizing that hitting or exceeding the 10-month rPFS benchmark could unlock a multi-billion-dollar market opportunity.

FibroGen emerges from 2025 leaner and better capitalized, with early but promising oncology and hematology assets now at the center of its story. For investors, the call underscored a classic high-risk, high-reward setup: a stronger balance sheet and compelling scientific rationale, balanced against falling revenues, execution risk, biomarker uncertainty, and an as-yet undefined path to commercialization.